TrialCurrent atherosclerosis reports2007

Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

Christopher T Dibble et al.PubMed ↗Publisher ↗

No numbers read from the abstract.